
MERCK & CO. INC.
MRKNYSETrading Snapshot
- Day Range
- $128.35 โ $132.16
- 52-Week Range
- $77.58 โ $135.05
- Volume
- $9.96B
- Avg Volume
- $10.68B
- Shares Outstanding
- 2.47B
- Next Earnings
- Sep 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $66.56B
- Last Q Revenue
- $17.70B
- P/E Ratio
- 100.1
- P/S Ratio
- 4.8x
- EPS (TTM)
- $1.25
- Dividend Yield
- 2.59%
Why Investors Own MRK
- โHigh-growth profile โ revenue up +50.7% YoY with expanding US Equity exposure.
- โHealthy economics โ 27% gross margin and 9% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About MERCK & CO. INC.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

Trump wants to split the MMR vaccine. Experts say that's unlikely โ and comes with consequences
Doctors and other experts say that splitting the measles, mumps and rubella shot has no scientific basis and is unlikely to get off the ground.
Argus Research Maintains Buy on Merck & Co, Raises Price Target to $145
Argus Research analyst Jasper Hellweg maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $130 to $145.

What Analysts Really Pressed LLY On This Quarter
Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.

Trump Cuts Core Childhood Vaccine Recommendations to 11, Bill Cassidy Says 'This Executive Order Is Wrong'
President Donald Trump signed an order Monday limiting core childhood vaccine recommendations to 11 vaccines.

Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
Recursion Pharmaceuticals, Inc. stock is a Hold: slow revenue, competition, cash burn & dilution risk despite Roche/Sanofi deals. Click for this RXRX update.

Stay informed with the top movers within the dow jones index on Monday.
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Monday.